Comparative effectiveness of teclistamab vs real-world physician's choice of therapy in the LocoMMotion and MoMMent studies for patients with triple-class exposed relapsed/refractory multiple myeloma

被引：0

作者：

Mateos, Maria-Victoria ^{[1
]}

van de Donk, Niels ^{[2
,3
]}

Delforge, Michel ^{[4
]}

Einsele, Hermann ^{[5
]}

De Stefano, Valerio ^{[6
]}

Lindsey-Hill, Joanne ^{[7
]}

Vincent, Laure ^{[8
]}

Kirkpatrick, Suriya ^{[9
]}

Besemer, Britta ^{[10
]}

Gonzalez Garcia, Maria Esther ^{[11
]}

Karlin, Lionel ^{[12
]}

Ghilotti, Francesca ^{[13
]}

Diels, Joris ^{[14
]}

Morano, Raul ^{[15
]}

Albrecht, Claire ^{[16
]}

Strulev, Vadim ^{[14
]}

Haddad, Imene ^{[16
]}

Pei, Lixia ^{[17
]}

Kobos, Rachel ^{[17
]}

Smit, Jennifer ^{[18
]}

Slavcev, Mary ^{[19
]}

Marshall, Alexander ^{[17
]}

Weisel, Katja ^{[20
]}

Moreau, Philippe ^{[21
]}

机构：

[1] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[2] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Hematol, Amsterdam, Netherlands

[3] Canc Ctr Amsterdam, Amsterdam, Netherlands

[4] Univ Leuven, Leuven, Belgium

[5] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[6] Catholic Univ, Fdn Policlin A Gemelli, IRCCS, Rome, Italy

[7] Nottinghamshire Univ Hosp NHS Trust, Nottingham, England

[8] CHU Montpellier, Montpellier, France

[9] Univ West England, Bristol, Avon, England

[10] Univ Hosp Tubingen, Tubingen, Germany

[11] Univ Hosp Cabuenes, Gijon, Spain

[12] Ctr Hosp Lyon Sud, Pierre Benite, France

[13] Janssen Cilag SpA, Cologno Monzese, Italy

[14] Janssen Pharmaceut NV, Beerse, Belgium

[15] Janssen Cilag, Madrid, Spain

[16] Janssen Cilag, Issy Les Moulineaux, France

[17] Janssen Res & Dev, Raritan, NJ USA

[18] Janssen Res & Dev, Spring House, PA USA

[19] Janssen Global Serv, Raritan, NJ USA

[20] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[21] Univ Hosp Hotel Dieu, Nantes, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-294

引用

页码：S199 / S199

页数：1

共 50 条

[21] Talquetamab vs Real-World Physician's Choice in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-Cell Maturation Antigen Therapy: Analyses of MonumenTAL-1 vs LocoMMotion/MoMMent
Mateos Manteca, Maria-Victoria
Jakubowiak, Andrzej
Einsele, Hermann
Schinke, Carolina
Besemer, Britta
Anguille, Sebastien
Manier, Salomon
Rasche, Leo
Goldschmidt, Hartmut
van de Donk, Niels
Perrot, Aurore
Teipel, Raphael
Karlin, Lionel
Scheid, Christof
San-Miguel, Jesus
Pawlyn, Charlotte
Martinez-Lopez, Joaquin
Cavo, Michele
Diels, Joris
Renaud, Thomas
Orel, Oleksiy
Cabrieto, Jedelyn
Perualila, Nolen
Weisel, Katja
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S69 - S70
[22] Real-Life Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Carfilzomib-and/or Pomalidomide-Based Regimens in the LocoMMotion and MoMMent Studies
Mateos Manteca, Maria-Victoria
Weisel, Katja
Gonzalez Garcia, Maria Esther
Einsele, Hermann
Lindsey-Hill, Joanne
De Stefano, Valerio
Besemer, Britta
Vincent, Laure
Kirkpatrick, Suriya
Karlin, Lionel
Goldschmidt, Hartmut
Conticello, Concetta
Roeloffzen, Wilfried
van de Donk, Niels
Delforge, Michel
Villanova, Pamella
Doyle, Margaret
Gray, Kathleen
Albrecht, Claire
Strulev, Vadim
Buyze, Jozefien
Squire, Jonathan
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S270 - S271
[23] Adjusted comparison of teclistamab versus physician's choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma
Mateos, Maria-Victoria
Chari, Ajai
Usmani, Saad
Goldschmidt, Hartmut
Weisel, Katja
Qi, Keqin
Londhe, Anil
Nair, Sandhya
Lin, Xiwu
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok
Marshall, Alexander
Slavcev, Mary
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S192 - S193
[24] Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites
Kumar, Shaji
Jagannath, Sundar
Weisel, Katja C.
Dachs, Laura Rosinol
Dimopoulos, Meletios-Athanasios
Siegel, David S.
Monge, Jorge
Leleu, Xavier
Du, Juan
de la Rubia, Javier
Lee, Jae Hoon
Mateos, Maria-Victoria
Gozzetti, Alessandro
Dytfeld, Dominik
Ocio, Enrique M.
Blade, Joan
Ozaki, Shuji
Nagaraj, Madhu
Hassan, Rafla
Green, Jeannette
Kroog, Glenn S.
Lorenc, Karen Rodriguez
Hampp, Christian
Ma, Qiufei
Durie, Brian G. M.
BLOOD, 2024, 144 : 7039 - 7041
[25] Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the United States
Madduri, Deepu
Hagiwara, May
Parikh, Kejal
Pelletier, Corey
Delea, Thomas E.
Kee, Arianna
Chari, Ajai
FUTURE ONCOLOGY, 2021, 17 (05) : 503 - 515
[26] Real-World Evaluation of Outcomes in Relapsed/Refractory Multiple Myeloma Patients That Are Triple-Class Exposed after Receiving 2 or More Prior Lines of Therapy
Radwanski, Katherine
Yu, Junhua
Pierce, Kody
Talati, Chetasi
Stricker, Steve
Jiao, Shiyin
Bueno, Orlando
BLOOD, 2023, 142
[27] Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Jagannath, Sundar
Lee, Hans C.
Richter, Joshua Ryan
Zonder, Jeffrey A.
Hoffman, James E.
Zhou, Zheng-Yi
Horton, Viviana Garcia
Fillbrunn, Mirko
Wang, Hongjue
Mattera, Matthew
Ma, Qiufei
Inocencio, Timothy J.
Xu, Yingxin
Bergrath, Evelien
Harnett, James
Roccia, Tito
Kroog, Glenn Scott
Rodriguez-Lorenc, Karen
Houvras, Yariv
Bumma, Naresh
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28] Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Roussou, Maria
Eleutherakis-Papaiakovou, Evangelos
Spiliopoulou, Vassiliki
Kastritis, Efstathios
Terpos, Evangelos
Dimopoulos, Meletios-Athanasios
Gavriatopoulou, Maria
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
[29] Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
Mateos, Maria-Victoria
Chari, Ajai
Usmani, Saad Z.
Goldschmidt, Hartmut
Weisel, Katja
Qi, Keqin
Londhe, Anil
Nair, Sandhya
Lin, Xiwu
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok
Marshall, Alexander
Slavcev, Mary
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (05): : 385 - 393
[30] Standard of care (SOC) outcomes in the last 3 years in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): the first pooled analysis of LocoMMotion and MoMMent trials
Weisel, Katja
Mateos, Maria-Victoria
Gonzalez Garcia, Maria Esther
Bittrich, Max
Lindsey-Hill, Joanne
De Stefano, Valerio
Besemer, Britta
Vincent, Laure
Kirkpatrick, Suriya
Karlin, Lionel
Goldschmidt, Hartmut
Conticello, Concetta
Roeloffzen, Wilfried
van de Donk, Niels
Delforge, Michel
Doyle, Margaret
Gray, Kathleen
Albrecht, Claire
Strulev, Vadim
Haddad, Imene
Saarinen, Silva
Mitchell, Lada
Buyze, Jozefien
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S217 - S218

← 1 2 3 4 5 →